Release date: July 25, 2006 (Accreditation Expired)
Program Description
Venous thromboembolism (VTE) is a major cause of morbidity and mortality in the United States. While unfractionated heparin (UFH) has been the standard treatment of VTE for many years, low-molecular-weight-heparins (LMWHs) are now commonly used as a therapeutic alternative. Effective prophylaxis and intervention are essential in minimizing VTE risk and reducing the incidence of life-threatening events. There exists a gap in knowledge for the treatment of VTE with secondary prophylaxis, acute PE, as well as a special consideration for the critically ill (e.g. volume overloaded) or patients with comorbidities (e.g. renal insufficiency). Furthermore, the existing clinical data needs to be discussed and interpreted in order to be applied, as well as a discussion surrounding current issues and controversies in VTE treatment and prophylaxis. This program provides concise and contemporary insight addressing concerns practitioners have regarding the management of patients with VTE.
Target Audience
This activity is intended for healthcare providers who treat DVT.
Educational Objectives
Upon completion of this educational activity participants will be able to:
Discuss the management of patients with venous thromboembolism: Challenges and Opportunities
Understand treatment and secondary prophylaxis in VTE
Discuss treatment options for management of acute PE
Understand the current issues and controversies in VTE treatment and prophylaxis
Discuss the new and current treatment options for DVT by examining current data
Identify special considerations for the medically ill or patients with comorbidities
The views and opinions expressed in this activity are those of the faculty. They do not reflect the views of Sanofi-Aventis, any other manufacturer of pharmaceuticals, ArcMesa Educators, or Scinexa, LLC.
The recommendations made in this program are based upon a combination of randomized clinical trials, current guidelines, and the clinical practice experience of the participating panelists. Any medications, diagnostic procedures or treatments discussed by the panelists should not be utilized without evaluation of their patient's conditions. Participants are urged to consult the full prescribing information on any drug mentioned in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication.
Printer settings may vary. Please use landscape layout option.
Paul E. Marik, MD, FCCP, FCCM Professor of Medicine
Director, Pulmonary and Critical Care Medicine
Thomas Jefferson University
Arthur P. Wheeler, MD, FCCP Associate Professor
Division of Allergy, Pulmonary and Critical Care Medicine
Vanderbilt University, School of Medicine
Director, Medical Intensive Care Unit
Jamie E. Siegel, MD Clinical Associate Professor of Medicine
Cardeza Foundation for Hematologic Research
Director, Hemophilia and Thrombosis Center
Thomas Jefferson University Hospital
Medical Director, Cardeza Foundation Special Hemostasis Laboratory
